How Checkpoint Inhibitors for Stage 4 Stomach Cancer Worked for Antonio
Learn how MSK helped a man with stage 4 stomach (gastric) cancer using checkpoint inhibitors, a type of immunotherapy that also treats many other cancers.
FDA Approves Adding Durvalumab Immunotherapy to Prevent Stomach and Esophageal Cancer Recurrence
Learn about a new approach helping to reduce the risk of stomach and esophageal cancer coming back after surgery, which has been approved by the FDA thanks to a clinical trial with immunotherapy led by researchers at MSK.
Adding Immunotherapy to Standard Treatment Before and After Surgery Helps Gastric and Gastroesophageal Cancer Patients Live Longer Without Cancer Recurrence
Adding immunotherapy to standard treatment both before and after surgery significantly improved outcomes for people with gastric and gastroesophageal adenocarcinoma (G/GEA), according to experts from Memorial Sloan Kettering Cancer Center (MSK). Results from the MATTERHORN trial, a global phase three study, were presented today at the annual American Society of Clinical Oncology meeting and simultaneously published in the New England Journal of Medicine (NEJM).
